FDA expands approval of breast cancer drug Kisqali
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
FDA expands approval for drug to treat early-stage breast cancer
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. NBC News' Kathy Park speaks to a woman who took the drug while it was in clinical trials and is now cancer free.
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will provide potential lifesaving Bria-IMT™ to those cancer patients in need beyond the scope of BriaCell’s pivotal Phase 3 clinical trial.
FDA expanded their approval on drug cancer drug
First News
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence,
Cure Today17h
Navigating the ‘Ever-Evolving Trajectory’ of Metastatic Breast Cancer
Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of ...
Medscape1d
Mental Health Considerations in Metastatic Breast Cancer: 5 Things to Know
The high prevalence of depression and anxiety among patients with MBC correlates with diminished survival rates and ...
PHILADELPHIA.Today on MSN6h
BriaCell Therapeutics Raises $8.5M After Positive Results for Experimental Cancer Therapy
BriaCell Therapeutics recently closed an $8.5 million stock sale after its positive results from mid-stage testing of its ...
Targeted Oncology17h
Elacestrant-Abemaciclib Combo Shows Promise for Breast Cancer
The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...
Oncolytics Biotech Reports Favorable Results For Breast Cancer Study
(RTTNews) - Clinical-stage company Oncolytics Biotech Inc. (ONCY), Thursday announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+ ...
WTKR10h
Friends of Norfolk artist diagnosed with breast cancer fulfill her dying wish
Kim Keene was not only a beloved artist, she was a mother and a business owner. She lost her battle with breast cancer, but her friends vow to carry on her mission of helping others.
The American Journal of Managed Care3d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
1 Ribociclib is manufactured by Novartis for early breast cancer and advanced or metastatic breast cancer. 2 The approval was supported by the NATALEE (NCT03701334) trial, a randomized, open ...
Targeted Oncology3d
A Closer Look at T-DXd in HER2-Positive Breast Cancer
Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...